All News

October 13, 2021

IDbyDNA Expands Scientific Advisory Board with Infectious Disease, Sequencing & FDA Leaders

On the heels of its appointment of Next-Generation Sequencing (NGS) leader Neil Gunn as CEO, IDbyDNA announces the addition of several notable leaders to their Scientific Advisory Board, including Dr. Adrian Egli, Dr. Tamara V. Feldblyum, Dr. Karl Voelkerding, Dr. Christopher Woods, and Dr. Stephen Young.

+ read more about IDbyDNA Expands Scientific Advisory Board with Infectious Disease, Sequencing & FDA Leaders

May 5, 2021

IDbyDNA Appoints Next-Gen Sequencing Executive Neil Gunn as New CEO

Infectious disease continues to be a leading cause of illness, morbidity and mortality around the world. In the fight to better understand all pathogens, including the SARS-CoV-2 lineage and its mutations, IDbyDNA, the pioneer in Precision Metagenomics, is focused on broadening availability for its Next-Generation Sequencing (NGS) targeted products. With that, the company has appointed NGS leader Neil Gunn as its new CEO to drive the next phase of growth.

+ read more about IDbyDNA Appoints Next-Gen Sequencing Executive Neil Gunn as New CEO

June 18, 2020

Metagenomics As a Tool To Diagnose and Understand COVID-19

IDbyDNA Chief Medical Officer Dr. Robert Schlaberg was just featured in an interview by Technology Networks, where he discusses how next-generation sequencing and metagenomics-based testing with the Explify Platform can address respiratory infections like SARS-CoV-2.

+ read more about Metagenomics As a Tool To Diagnose and Understand COVID-19

January 29, 2020

IDbyDNA Raises $20 Million in Series B Financing to Continue Advancements in Infectious Disease Diagnosis and Pathogen Identification

IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification, and interpretation of microorganisms and their role in human health, today announced the raise of $20 million in its Series B financing led by ARTIS Ventures and joined by Genesys Capital and others.

+ read more about IDbyDNA Raises $20 Million in Series B Financing to Continue Advancements in Infectious Disease Diagnosis and Pathogen Identification

January 28, 2020

Novel Wuhan Coronavirus Detectable with IDbyDNA Explify Respiratory Test

IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification and interpretation of microorganisms and their role in human health, today announced that its currently available Explify Respiratory test can detect 2019-nCoV in addition to over 900 other viral, bacterial, fungal and parasitic pathogens.

+ read more about Novel Wuhan Coronavirus Detectable with IDbyDNA Explify Respiratory Test